You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company plans to develop a liquid biopsy assay that can identify patients most likely to benefit from treatment with checkpoint inhibitors.
Mathais Lichterfeld of the Ragon Institute and Rushdy Ahmad of the Broad Institute will use high-throughput proteomics to find phosphorylation important to HIV replication.
NIH has been conservative on the PMI's budget and its funds are sufficient to launch enrollment next year, begin collecting data, and initiate genetic testing pilot projects.
Personalized medicine proponents are uncertain where funding, personnel, and priorities will land in a new administration and Congress.
Translational scientist Jacqueline Achkar of Albert Einstein Medical College will lead several collaborations to build a point-of-care diagnostic platform.
The VP lauded the work of the assembled researchers, offered suggestions for ways forward, and asked for their help in determining how to change the system for the better.
The grants are strictly for new research, but Rice University scientist David Zhang is always looking for commercialization opportunities with his startup, Searna.
The grant will support the day-to-day running, maintenance, and care of the supercomputer through the year 2020.
President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.
The SBIR grant could be worth as much as $2.3 million and will help PapGene develop and commercialize its proprietary ovarian and endometrial cancer detection test.
The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.
New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.
In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.
Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.